Physician profile
Christopher B Green
NPI 1700897774
$8,684.74
in general payments reported to CMS, 2019-2025
32 companies · $994 in 2025
The $994 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $1,471 · 2021: $1,709 · 2022: $1,114 · 2023: $1,008 · 2024: $1,189 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,759.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,277.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $562.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $556.45 | 2019-2023 | |
| Allergan, INC. | $527.75 | 2019-2020 | |
| Abbvie INC. | $474.43 | 2021-2024 | |
| Abbott Laboratories | $434.90 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $434.80 | 2021-2025 | |
| Amarin Pharma, INC. | $425.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $373.40 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.79 | 2021-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $273.99 | 2019-2022 | |
| Amgen INC. | $190.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Eisai INC. | $169.80 | 2020-2022 | |
| Pfizer INC. | $166.51 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $120.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $94.09 | 2023-2025 | Veozah |
| Dexcom, INC. | $79.09 | 2021-2025 | Dexcom G6 Transmitter |
| Endo Pharmaceuticals INC. | $67.65 | 2019-2021 | |
| Exact Sciences Corporation | $64.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $58.80 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.46 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.62 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.89 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2022 | |
| Genentech USA, INC. | $20.49 | 2019 | |
| Medtronic Vascular, INC. | $15.83 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.10 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.38 | 2020 | |
| Hikma Pharmaceuticals USA | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.